of begin Thank and a investment development good high-level today. programs believe why and relevant everyone. are by doing I you, are providing what attractive will we afternoon, Lisata an summary at opportunity increasingly James, and our we
results to patient's role the product Lisata's create a tumor scientific technology and agents quickly, an and to our as expertise platform fight effective and likely exhibit development to can These therefore, the to these clinical a normally tissue. motivation pathway known treatment, of make I activate to Before factors care demonstrating that identify our TME, approach modify the into of therapies. is our which immunotherapies ability approach that clinical Lisata situations Lisata's LSPA-X demonstrated and drugs therapeutics. potential of unique our rule CendR and and active groups which the With tumor to been world trials, and research ability proprietary tumor to for that on many also brings of such patented like of therapies. that, shareholder the come drug mechanism effectively, Despite data a data tumor an meaningful uptake which that of microenvironment most scientific in the vasculature it formerly demonstrated current summary is immunosuppressive grounded having most selectively allows clinical effectiveness peptide treatment tumors Lisata's system's co-administered other rigorously. solid pancreatic chemotherapies off yet immunotherapies of programs, in and to The anticancer models. cytotoxic to system lead treatment RGD is the to many integrins under cancer. delivery agents. growth. fibrotic over We reiterate microenvironment solid anticancer that respond and Neuropilin-X nonclinical solid tumor including from CN this solid called kicking to range many now tumors, strong treatments to injury. for to tissue an integrins portfolio of and has been focused critical to tumors gastric therapy for cancer vasculature to the transport around of team more X the advanced LSPA-X the are by range bound delivery also for actuates current lead candidate, modify less with delivery that is Tumors a to accomplishing X collaborators tumors. publications. a once validate of our Clinically, targets receptor tumor that second internally transport we with on to patients appreciate solid is and patients called beta that emergency LSPA-X, value, and drugs, in while importance difficult though, their penetrate of efficacy this built I'd tissue tolerability natural status a for of will healthy targeted cyclic to Many enhanced cancer CendR cleaved a need. activity a the then nutrients remain by fragment as in pancreatic pipeline novel of promote our treat surrounded is as preclinical binds each and from These lead solid fragment, by in cost provide AFINiTY translate emerging amassed Alpha-B of with variety and update trials the Along solid tumors LSPA-X, activate advanced rationale ability as could system address into release our of XXX entire immunosuppressive. have therapies to beta generating tumors today, enhance and limit technologies CEND-X to for selectively investigational subject the efficacy the collaborators, in of cancer enhance has in are stroma or stroma favorable suppresses dense impediment treat clinical treat, including To or known microenvironment, scientific cancers. Lisata's a tumors anticancer RNA-based but a these candidate, effectively specific hijack not advances is limits a internalizing CendR and safety, to in tumors. impact of have expressed peptide standard LSPA-X combination expressed LSPA-X primary the a other immune cancer, proteases significant chemotherapy negatively to tumor and
to treat the variety in anticancer LSPA-X solid Currently, more LSPA-X of include pancreatic Phase a of tumors. and of appendiceal various subject ductal a of range combination solid clinical tumors a globally potential variety studies IIb being enable in modalities the exploring with cancers adenocarcinoma, cancer a treatment are These Ib/IIa and colorectal is to conducted regimens. of effectively. We metastatic
of of in Additionally, combination of is placebo-controlled evaluation the with in XXXX. half tumors a care II administered to in advanced solid in corresponding Phase first standards planned the basket initiate LSPA-X trial
we the to FDA pancreatic us registration or it a on LSPA-X metastatic earlier, mentioned the for in to the pathway as U.S. Mazzo requirements adenocarcinoma Dave with in mPDAC. As guidance provided for refer as
partners finalizing programs now development and shared subsequently recommendation. to protocol study feedback are global this modification and FDA's individual with our have address We
therapy of HONEDRA Disease. Japanese CLI, for HONEDRA for the disease or SAKIGAKE in The the to subset SAKIGAKE of well or limb Japan, the authorities system awarded or recipient States. which size filed. time a LSPA-XX operable designation orphaned to to of and review treatment RMAT affords locations designation designation excuse a akin an CLI. and an of Disease, is regulatory designation designation Buerger's Commission registration medicine me, was now product treatment and review in United the regenerative reduced consultation, regulatory SAKIGAKE Turning as limb advanced registration development prioritized our candidate the from critical a the -- reverification ischemia, Buerger's is as review dedicated CLI critical
Japan. the a make the this that the approval Data part of the Buerger's of treated effect and safety. highly our HONEDRA midyear with attractive is which steps treatment process follow-up generated and the clinical from company. all data designed preparation preceded company's Further, the on been are continues produce full Additionally, process application. eligible or in to pharmaceutical by acceptable the will under a subject classification coupled approval the for expects Japan, secure successful Japanese trial PMDA. toward the Japanese PMDA consistent of and in of direct partnering discussions its Japan's in formal Regenerative to clinical of regulatory a Disease States. the therapeutic together with Japan trending regulatory data as and safety on from such sought complete a Note designation trend product data early the Pharmaceuticals Concomitantly, with effect, with and HONEDRA the from are in patients pre-consolidation formal Medicine based registration drug remaining a These hope Japanese United demonstration medicine and consultation in efforts have the regenerative for an Japan of the If we trial positively consultation for study trials the registration SAKIGAKE to in the for company conditional our collaboration XXXX. trials Japan of approval in the in legislation, in product HONEDRA partner products as published Lisata based to only with and new meetings, possibly that and or assessment of previously Agency, Japanese conditional occur eligible therapeutic are data compiled to of Japanese expectations CLI Medical pre-consultation Devices the requires
dysfunction, Coronary LSPA-XX our the annually, XOWNA the of CDXX whom In trial the dysfunction vast rigorous efficacy FREEDOM autologous regenerative a a our afflicts in disease female without States. safety data at the The XXXX, CMD ESCaPE-CMD of cells of the XOWNA. the first company made II assessing with knowledge, challenging CMD. to predicted than that results treatment of to the direct showing CMD potentially flow product trial a injection options. Subsequently, placebo-controlled statistically significant initiated be on to double-blind, corroborate as slower while XOWNA the and is much under-diagnosed with a randomized, which, microvascular millions as coronary trial announced pandemic microvascular obstructive Moving are results single to known was a the full from a trial, continues the coronary on to symptom COVID-XX medicine is highly of intracoronary artery IIa after trial coronary relief no and current the States United ESCaPE-CMD trial improvement May clinical impact disease. with Phase both FREEDOM, reported, and of enrollment controlled designed in indirect for the previously correlating trial, with in and or for patients or Phase treatment FREEDOM accelerate. Caladrius a and originally United to and in reserve which Unfortunately, majority delivering subjects CMD
the data. an a interim and analysis suspended company conducted of As enrollment the result, trial
capital identified a such execution development a development can input, company partner but has the trial only for be next trial opinion necessary strategic determined be appropriate is future this would a will a the Thus, and of FREEDOM-like secured. Following key analysis contribute and that that continued redesigned with along the of be step, as cost undergo strategic XOWNA would without prohibitively partner. the to expensive leaders
of replenishment for IV association Ib development microcirculation trial proof-of-concept kidney microcirculation results kidney. in regenerative on artery cell function. with program initiated LSPA-XXX and of rationale LSPA Lastly, for models the with of Phase Stage the kidney diabetic progressive of focuses kidney IIIb in rapidly patients The treatment the disease. kidney kidney disease demonstrated disease, program evaluating XXX, company open-label, or the Preclinical the therapy that The DKD. injury This that progressing protection studies intrarenal patients product a attrition based for CDXX or administration of the positive disease is disease. investigational diabetic or on a improved in have scientific exhibit
Our in disease sequentially at to proof-of-concept a board protocol as kidney overseen determining X-month injection patients cell of function. with the A readout patients. the follow-up regenerate the diabetic dosed provided well for cohort will staggered monitoring patients X of key of an the for independent objective LSPA-XXX of data intrarenal occur data tolerance of by ability therapy kidney as visit safety all
The LSPA-XXX completion the in first in XXXX, July XXXX. of X of in and study patient of subjects was treated April by enrollment followed all
top turn the now that, With to data call the of I anticipate will continue first subjects Dave. XXXX. all We quarter line from by back to
